SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma

Chang, Chia‐Ming; Cho, Shih‐Feng; Chen, Yu‐Wen; Tu, Hung-Pin; Lin, Chia-Yang; Chang, Chih‐Hau

doi:10.1097/rlu.0b013e318251e16e

Cited by 24 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 8 Increased cell proliferation rate and enhanced expression of hexokinase type-II and glucose transporter-1 may also contribute to increased FDG uptake in tumor cells on delayed imaging. 19 , 20 And longer time of imaging allows improved blood pool and urinary tract clearance, thus lower FDG back ground. Most normal tissues and benign diseases have decreased background activity and most malignant ones have increased FDG uptake on delayed imaging, leading a higher lesion-to-background ratios, thus higher sensitivity.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

et al. 2015

View full text Add to dashboard Cite

To assess the clinical value of dual time point imaging (DTPI) fluorine-18fludeoxyglucose (18F-FDG) positron emission tomography (PET)/CT in differentiating malignancy and benign disease of patients with focally increased gastric uptake.Patients who present focally increased 18F-FDG uptake in gastric wall on conventional PET/CT imaging received delayed imaging. PET/CT scans were acquired at 1 and 2 hours (early and delayed imaging) after 18F-FDG injection. The maximum standardized uptake value (SUV) was calculated. The SUVmax of the early and delayed imaging acquisition were signed S1 and S2, respectively. The receiver operating characteristic curve (ROC) of the S1, S2, and the retention index (RI) were drawn to find the best cut-off point value for differential diagnosis. Sensitivity, specificity, Youden index, and the area under the curve (AUC) were calculated, respectively.From September 2010 to May 2015, 74 patients (56 male and 18 female; age of 57 ± 12 years; range, 32–86 years) referring for areas of focally increased uptake of 18F-FDG in gastric wall received delayed imaging. The S1 was 5.0 ± 1.4 (range, 1.9–11.3), and S2 was 5.9 ± 2.7 (range, 1.0–16.3). The SUVmax were increased in 52 patients in delayed imaging, with 85% (44/52 cases) appeared malignant; decreased in 20 patients, and 90% (18/20 cases) were benign; 2 patients of benign had not changed. The change of SUVmax between malignant and benign was significant difference (t = −5.785, P = 0.000).Taking the S1, S2, and RI higher than 4.6%, 5.1%, and 13% as positive diagnostic criteria, the sensitivity were 65.2%,87.0%, and 87.0%, respectively; the specificity were 64.3%, 82.1%, and 89.3%; the Youden index were 0.332, 0.693, and 0.770; AUC were 0.635 (95% confidence intervals (95% CI) 0.507–0.764), 0.873 (95% CI, 0.786–0.961), and 0.923 (95% CI, 0.854–0.992).DTPI is more precise to distinct malignant from benign gastric diseases compared with conventional imaging, and it is readily accessible.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…13 In addition, malignant cells bear higher numbers of glucose transporters and high levels of hexokinase enzyme, which enhances the effect mentioned earlier. 6,14 Several studies have used DTPI in normal and abnormal states, including in lung, 5,[15][16][17][18][19] breast (Table 1), [20][21][22][23][24][25] head and neck, 3,26 and pancreatic 27 cancers; atherosclerosis ( Fig. 1) 28,29 ; and many other settings (Fig.…”

Section: Introductionmentioning

confidence: 99%

Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings

et al. 2016

View full text Add to dashboard Cite

“…Although PET/CT for assessing DLBCL patients is widely implemented in daily clinical practice , only limited data are presently available to describe the role of PET/CT quantitative parameters for the prediction of outcome, especially for those newly employed. The findings are discordant being them alternatively allotted as valuable or worthless . At this time, the metabolic tumor volume (MTV) and the total lesion glycolysis (TLG) are measures of the metabolic activity of tumors derived from the F‐18 FDG uptake on PET/CT images.…”

mentioning

confidence: 99%

F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma

Gallicchio

Mansueto

Simeon

et al. 2014

European J of Haematology

View full text Add to dashboard Cite

show abstract

SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma

Cited by 24 publications

References 46 publications

Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings

F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About